Filing Flows › Haemonetics (HAE) › Q2 FY26
Haemonetics (HAE) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Nov 6, 2025
Haemonetics (HAE) reported revenue of $327M for the second quarter fiscal 2026 (Q2 FY26), -5% from a year earlier and +2% from the quarter before. Operating margin was 17.9%, net earnings $38.7M (11.8% of revenue).
Haemonetics, Q2 FY26: revenue $327M (-5% year over year), operating margin 17.9%, net earnings $38.7M, operating cash flow $111M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $327M | +2% | -5% |
| Gross profit | $195M | +1% | +4% |
| Operating profit | $58.5M | +9% | +13% |
| Net earnings | $38.7M | +14% | +14% |
| Operating cash flow | $111M | +540% | +128% |
| Free cash flow | $106M | +679% | +170% |
What changed
Revenue was $327.3M in Q2 FY26, down 5% year over year and up 2% from the previous quarter. Hospital was the largest line at 44% of revenue. Plasma lost $13.2M year over year (down 10%), 73% of the total change.
Gross margin was 59.5%, up 5.2 points from a year earlier. Operating profit was $58.5M, a 17.9% margin (up 2.9 points year over year). Operating expenses grew 0% against a revenue fall of 5%. The fastest-growing cost line was Other operating costs (+35%). Net earnings were $38.7M, up 14% year over year. The effective tax rate was 24.6%.
Operating cash flow was $111.3M (up 128% year over year), 288% of net earnings. Non-cash charges added back $28.3M of depreciation and amortization and $7.6M of share-based compensation. Working capital and other items added $36.8M. Capital expenditures of $5.0M left free cash flow of $106.3M.
Questions
What was Haemonetics' revenue in the second quarter fiscal 2026?
Haemonetics (HAE) reported revenue of $327M for the second quarter fiscal 2026 (Q2 FY26), -5% from a year earlier and +2% from the quarter before.
Was Haemonetics profitable in the second quarter fiscal 2026?
Operating profit was $58.5M (17.9% of revenue) and net earnings $38.7M.
Source: Haemonetics 10-Q on SEC EDGAR.